Literature DB >> 29038903

[Nontuberculous mycobacteria in sputum : Recommendations for diagnosis and treatment].

J Rademacher1.   

Abstract

Pulmonary diseases caused by nontuberculous mycobacteria (NTM) have increased over the last years and decades in Germany and also worldwide. Because the disease is more frequent in patients with immunodeficiencies and chronic respiratory diseases, e.g. bronchiectasis, advanced chronic obstructive lung disease (COPD) and cystic fibrosis (CF), an infection with mycobacteria should always be considered in this patient group. The detection in sputum alone is not an indication for treatment but the correct diagnosis should be based on the appropriate clinical symptoms as well as radiological and microbiological criteria. The diagnosis is often delayed because the symptoms are unspecific. The treatment of pulmonary NTM disease is difficult and tedious and for these reasons is often prematurely terminated. Adherence of treating physicians to the guidelines is also conspicuously low. Before starting treatment, it is important to carefully define the goals and clarify the risks and benefits of the treatment with the patient. As adverse toxic events can occur during treatment, it should be closely monitored. In the case of an infrequent pathogen or a severe course of the disease, referral to an NTM specialist center should be undertaken.

Entities:  

Keywords:  Antibiotics; Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis; Drug toxicity

Mesh:

Substances:

Year:  2017        PMID: 29038903     DOI: 10.1007/s00108-017-0330-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  37 in total

1.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Steven McNulty; Julie V Philley; Jessica Killingley; Rebecca W Wilson; Deanna S York; Sara Shepherd; David E Griffith
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

2.  Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease.

Authors:  David E Griffith; Jennifer Adjemian; Barbara A Brown-Elliott; Julie V Philley; D Rebecca Prevots; Christopher Gaston; Kenneth N Olivier; Richard J Wallace
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

Review 3.  Pulmonary disease caused by nontuberculous mycobacteria.

Authors:  Curtis H Weiss; Jeffrey Glassroth
Journal:  Expert Rev Respir Med       Date:  2012-12       Impact factor: 3.772

Review 4.  Microbiological features and clinical relevance of new species of the genus Mycobacterium.

Authors:  Enrico Tortoli
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 5.  The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review.

Authors:  S K Brode; C L Daley; T K Marras
Journal:  Int J Tuberc Lung Dis       Date:  2014-11       Impact factor: 2.373

6.  In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.

Authors:  Remedios Guna; Carlos Muñoz; Victoria Domínguez; Angeles García-García; Jorge Gálvez; Jesús-Vicente de Julián-Ortiz; Rafael Borrás
Journal:  J Antimicrob Chemother       Date:  2005-04-11       Impact factor: 5.790

7.  Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease.

Authors:  Y Ito; T Hirai; K Maekawa; K Fujita; S Imai; S Tatsumi; T Handa; H Matsumoto; S Muro; A Niimi; M Mishima
Journal:  Int J Tuberc Lung Dis       Date:  2012-01-05       Impact factor: 2.373

Review 8.  Therapy of nontuberculous mycobacterial disease.

Authors:  David E Griffith
Journal:  Curr Opin Infect Dis       Date:  2007-04       Impact factor: 4.915

9.  The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study.

Authors:  Wouter Hoefsloot; Jakko van Ingen; Claire Andrejak; Kristian Angeby; Rosine Bauriaud; Pascale Bemer; Natalie Beylis; Martin J Boeree; Juana Cacho; Violet Chihota; Erica Chimara; Gavin Churchyard; Raquel Cias; Rosa Daza; Charles L Daley; P N Richard Dekhuijzen; Diego Domingo; Francis Drobniewski; Jaime Esteban; Maryse Fauville-Dufaux; Dorte Bek Folkvardsen; Noel Gibbons; Enrique Gómez-Mampaso; Rosa Gonzalez; Harald Hoffmann; Po-Ren Hsueh; Alexander Indra; Tomasz Jagielski; Frances Jamieson; Mateja Jankovic; Eefje Jong; Joseph Keane; Wo-Jung Koh; Berit Lange; Sylvia Leao; Rita Macedo; Turid Mannsåker; Theodore K Marras; Jeannette Maugein; Heather J Milburn; Tamas Mlinkó; Nora Morcillo; Kozo Morimoto; Dimitrios Papaventsis; Elia Palenque; Mar Paez-Peña; Claudio Piersimoni; Monika Polanová; Nalin Rastogi; Elvira Richter; Maria Jesus Ruiz-Serrano; Anabela Silva; M Pedro da Silva; Hulya Simsek; Dick van Soolingen; Nora Szabó; Rachel Thomson; Teresa Tórtola Fernandez; Enrico Tortoli; Sarah E Totten; Greg Tyrrell; Tuula Vasankari; Miguel Villar; Renata Walkiewicz; Kevin L Winthrop; Dirk Wagner
Journal:  Eur Respir J       Date:  2013-04-18       Impact factor: 16.671

Review 10.  Update on the epidemiology of pulmonary nontuberculous mycobacterial infections.

Authors:  Brian A Kendall; Kevin L Winthrop
Journal:  Semin Respir Crit Care Med       Date:  2013-03-04       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.